Abstract
Objective
The
aim of this study was to compare the serum CA125 regression in advanced
ovarian carcinoma patients treated with paclitaxel/platinum
(TP) and platinum/epirubicin/ifosfamide (PAC) during
early chemotherapy. The relationship between survival and CA125
regression
during first line chemotherapy was evaluated.
Conclusion
There
isn’t significant difference in serum CA125 regression between patients
who are treated with PAC or PT during early
chemotherapy. CA125 half-life and nadir CA125
concentration are independent prognostic factor in advanced ovarian
cancer.
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.